Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 116 articles:
HTML format
Text format



Single Articles


    April 2016
  1. MENIN C, Bojnik E, Del Bianco P, Elefanti L, et al
    Differences in telomere length between sporadic and familial cutaneous melanoma.
    Br J Dermatol. 2016 Apr 7. doi: 10.1111/bjd.14652.
    PubMed     Text format     Abstract available


  2. GALLAIS SEREZAL I, Beaussant Y, Rochigneux P, Tournigand C, et al
    End-of-life care for hospitalised patients with metastatic melanoma in France: a nationwide, register-based study.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14631.
    PubMed     Text format     Abstract available


  3. HORSHAM C, J Loescher L, Whiteman DC, Soyer HP, et al
    Consumer acceptance of patient-performed mobile teledermoscopy for the early detection of melanoma.
    Br J Dermatol. 2016 Apr 1. doi: 10.1111/bjd.14630.
    PubMed     Text format     Abstract available


  4. OREGAARD JS, Jarjis RD, Venzo A, Jemec B, et al
    Cover Image: Unique presentation of a subungual malignant melanoma in situ.
    Br J Dermatol. 2016;174:935.
    PubMed     Text format    


  5. SULLIVAN RJ
    Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.
    Br J Dermatol. 2016;174:716-7.
    PubMed     Text format    


  6. BAADE PD
    Quantifying the mortality burden for skin cancers other than melanoma.
    Br J Dermatol. 2016;174:713-4.
    PubMed     Text format    


    March 2016
  7. UGUEN A
    Discrepant mutational status between naevi and melanomas in naevus-associated melanomas: about mutation-specific immunohistochemistry.
    Br J Dermatol. 2016 Mar 31. doi: 10.1111/bjd.14603.
    PubMed     Text format     Abstract available


  8. PARKINS G, Brown E, Gupta G
    Radiological imaging in all stage III melanoma- current practice in the United Kingdom.
    Br J Dermatol. 2016 Mar 15. doi: 10.1111/bjd.14551.
    PubMed     Text format     Abstract available


    February 2016
  9. CHAPPUIS P, Duru G, Marchal O, Girier P, et al
    Dermoscopy: A useful tool for general practitioners in melanoma screening: A nationwide survey.
    Br J Dermatol. 2016 Feb 23. doi: 10.1111/bjd.14495.
    PubMed     Text format     Abstract available


  10. STASER K, Chen D, Solus J, Rosman IS, et al
    Extensive tumoral melanosis associated with ipilimumab-treated melanoma.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14474.
    PubMed     Text format     Abstract available


  11. SARGEN MR, Merrill SL, Chu EY, Nathanson KL, et al
    CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic nevi, and internal malignancies: A case series and review of the literature.
    Br J Dermatol. 2016 Feb 15. doi: 10.1111/bjd.14485.
    PubMed     Text format     Abstract available


  12. NALDI L, Cazzaniga S
    Prediction of high total naevus count to estimate melanoma risk. We need more, don't we?
    Br J Dermatol. 2016;174:261-2.
    PubMed     Text format    


    January 2016
  13. MULLER C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al
    Characterization of high risk melanoma patients in Austria.
    Br J Dermatol. 2016 Jan 22. doi: 10.1111/bjd.14407.
    PubMed     Text format     Abstract available


  14. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.
    Br J Dermatol. 2016 Jan 20. doi: 10.1111/bjd.14279.
    PubMed     Text format    


  15. CHMIELOWSKI B
    Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.
    Br J Dermatol. 2016;174:20.
    PubMed     Text format    


    December 2015
  16. FERNANDEZ-VEGA I, Santos-Juanes J, Fresno-Forcelledo MF
    Primary amelanotic rhabdoid melanoma of the forehead.
    Br J Dermatol. 2015 Dec 29. doi: 10.1111/bjd.14382.
    PubMed     Text format     Abstract available


  17. ROACH RE, Plasmeijer EI, van Doorn R, Bergman W, et al
    The value of clinical characteristics for the diagnosis of melanoma in patients presenting at a pigmented lesion clinic.
    Br J Dermatol. 2015 Dec 26. doi: 10.1111/bjd.14375.
    PubMed     Text format     Abstract available


  18. EISEMANN N, Jansen L, Castro FA, Chen T, et al
    Survival from non-melanoma skin cancer in Germany.
    Br J Dermatol. 2015 Dec 16. doi: 10.1111/bjd.14352.
    PubMed     Text format     Abstract available


  19. FRAUCHIGER AL, Mangana J, Rechsteiner M, Moch H, et al
    Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status.
    Br J Dermatol. 2015 Dec 13. doi: 10.1111/bjd.14347.
    PubMed     Text format     Abstract available


  20. CURL PK
    Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment.
    Br J Dermatol. 2015;173:1365-6.
    PubMed     Text format    


    November 2015
  21. TSCHANDL P, Berghoff AS, Preusser M, Pammer J, et al
    Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and nevi in vivo.
    Br J Dermatol. 2015 Nov 28. doi: 10.1111/bjd.14323.
    PubMed     Text format     Abstract available


  22. MONCRIEFF M, Fadhil M, Garrioch J
    Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience.
    Br J Dermatol. 2015 Nov 24. doi: 10.1111/bjd.14314.
    PubMed     Text format     Abstract available


  23. GUIDA S, Pellacani G, Cesinaro AM, Moscarella E, et al
    Spitz naevi and melanomas with similar dermoscopic pattern: can confocal microscopy differentiate?
    Br J Dermatol. 2015 Nov 11. doi: 10.1111/bjd.14286.
    PubMed     Text format     Abstract available


  24. SEBARATNAM DF, Anforth R, Fernandez-Penas P
    Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma.
    Br J Dermatol. 2015 Nov 2. doi: 10.1111/bjd.14264.
    PubMed     Text format     Abstract available


    October 2015
  25. RIBERO S, Zugna D, Osella-Abate S, Glass D, et al
    Prediction of high naevus count in a healthy UK population to estimate melanoma risk.
    Br J Dermatol. 2015 Oct 19. doi: 10.1111/bjd.14216.
    PubMed     Text format     Abstract available


    September 2015
  26. MOSER J, Moshammer R, Koglbauer G, Kitzwogerer M, et al
    Sentinel-node biopsy in melanoma: A single center experience with 216 consecutive patients.
    Br J Dermatol. 2015 Sep 24. doi: 10.1111/bjd.14189.
    PubMed     Text format     Abstract available


  27. ZARAGOZA J, Caille A, Beneton N, Bens G, et al
    Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
    Br J Dermatol. 2015 Sep 6. doi: 10.1111/bjd.14155.
    PubMed     Text format     Abstract available


  28. MATTER-WALSTRA K, Braun R, Kolb C, Ademi Z, et al
    A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.
    Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152.
    PubMed     Text format     Abstract available


  29. KRAFT S, Tsao H
    Melanoma-associated naevi: precursors or coincidence?
    Br J Dermatol. 2015;173:633-4.
    PubMed     Text format    


  30. SCHOFIELD JK
    Sentinel lymph node biopsy: in support of equity of access, informed shared decision making and patient choice.
    Br J Dermatol. 2015;173:863-4.
    PubMed     Text format    


    August 2015
  31. MONCRIEFF M, Garioch J
    MSLT-I: it's all about the lymph nodes....
    Br J Dermatol. 2015;173:626-7.
    PubMed     Text format    


  32. MCGREGOR JM, Sasieni P
    MSLT-I: it's all about the lymph nodes...: reply from the authors.
    Br J Dermatol. 2015;173:627-8.
    PubMed     Text format    


    July 2015
  33. BENATI E, Argenziano G, Kyrgidis A, Moscarella E, et al
    Melanoma and naevi with globular pattern: Confocal microscopy as an aid for diagnostic differentiation.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14049.
    PubMed     Text format     Abstract available


  34. LALLAS A, Kyrgidis A, Koga H, Moscarella E, et al
    The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma.
    Br J Dermatol. 2015 Jul 25. doi: 10.1111/bjd.14045.
    PubMed     Text format     Abstract available


  35. LI Z, Wang Z, Yu Y, Zhang H, et al
    Smoking is Inversely Related to Cutaneous Malignant Melanoma -Says Results from a Meta-analysis.
    Br J Dermatol. 2015 Jul 2. doi: 10.1111/bjd.13998.
    PubMed     Text format     Abstract available


  36. DAVIES MA
    BRAF in early stage melanoma: rationale for testing and treatment?
    Br J Dermatol. 2015;173:9-10.
    PubMed     Text format    


  37. GOHARA M
    Skin cancer: an African perspective.
    Br J Dermatol. 2015;173 Suppl 2:17-21.
    PubMed     Text format     Abstract available


    June 2015
  38. SINHA R, Larkin J, Gore M, Fearfield L, et al
    Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Br J Dermatol. 2015 Jun 24. doi: 10.1111/bjd.13958.
    PubMed     Text format     Abstract available


  39. FINNANE A, Soyer HP
    Smartphone diagnosis of skin cancer: there's not yet an app for that.
    Br J Dermatol. 2015;172:1474-5.
    PubMed     Text format    


  40. WU S
    Do mutations in BRCA1/BRCA2 confer a higher risk of skin cancer?
    Br J Dermatol. 2015;172:1473.
    PubMed     Text format    


  41. GUMASTE PV, Penn LA, Cymerman RM, Kirchhoff T, et al
    Skin cancer risk in BRCA1/2 mutation carriers.
    Br J Dermatol. 2015;172:1498-506.
    PubMed     Text format     Abstract available


  42. VIGARIOS E, Lamant L, Delord JP, Fricain JC, et al
    Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Br J Dermatol. 2015;172:1680-2.
    PubMed     Text format    


    May 2015
  43. THOMAS L
    Dermoscopy for melanoma: don't forget to take a photo.
    Br J Dermatol. 2015;172:1182-3.
    PubMed     Text format    


    April 2015
  44. JAFARI SM, Hunger RE, Shafighi M
    Lack of strong evidence in depth of thick melanoma excision.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13871.
    PubMed     Text format     Abstract available


  45. PIZZICHETTA MA, Kittler H, Stanganelli I, Bono R, et al
    Pigmented nodular melanoma: The predictive value of dermoscopic features using a multivariate analysis.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13861.
    PubMed     Text format     Abstract available


  46. SHITARAA D, Tell-Marti G, Badenas C, Enokihara MM, et al
    Mutational status of nevus associated-melanomas.
    Br J Dermatol. 2015 Apr 9. doi: 10.1111/bjd.13829.
    PubMed     Text format     Abstract available


  47. MARCHIORI BAKOS R
    Dermoscopy of naevoid melanoma.
    Br J Dermatol. 2015;172:848-9.
    PubMed     Text format    


  48. IDORN LW
    New insights into the association of socioeconomic status with cutaneous malignant melanoma.
    Br J Dermatol. 2015;172:846-7.
    PubMed     Text format    


  49. OAKLEY AM
    Mobile teledermatology is here to stay.
    Br J Dermatol. 2015;172:856-7.
    PubMed     Text format    


  50. MANAHAN MN, Soyer HP, Loescher LJ, Horsham C, et al
    A pilot trial of mobile, patient-performed teledermoscopy.
    Br J Dermatol. 2015;172:1072-80.
    PubMed     Text format     Abstract available


  51. DEBARBIEUX S, Gaspar R, Depaepe L, Dalle S, et al
    Intraoperative diagnosis of nonpigmented nail tumours with ex vivo fluorescence confocal microscopy: 10 cases.
    Br J Dermatol. 2015;172:1037-44.
    PubMed     Text format     Abstract available


    March 2015
  52. MAR VJ, Liu W, Devitt B, Wong SQ, et al
    The role of BRAF mutations in primary melanoma growth rate and survival.
    Br J Dermatol. 2015 Mar 5. doi: 10.1111/bjd.13756.
    PubMed     Text format     Abstract available


  53. FARIES MB, Cochran AJ, Elashoff RM, Thompson JF, et al
    Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: Response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal
    Br J Dermatol. 2015;172:571-3.
    PubMed     Text format     Abstract available


  54. SLADDEN M, Zagarella S, Popescu C, Bigby M, et al
    No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.
    Br J Dermatol. 2015;172:566-71.
    PubMed     Text format     Abstract available


  55. ATTARD NR
    Head and neck melanoma: pattern of sun exposure and histological subtypes.
    Br J Dermatol. 2015;172:560-1.
    PubMed     Text format    


  56. SWETTER SM
    Thinner melanomas and improved survival among men in Sweden from 1997 to 2011.
    Br J Dermatol. 2015;172:559-60.
    PubMed     Text format    


  57. MCGREGOR JM, Sasieni P
    Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice.
    Br J Dermatol. 2015;172:552-4.
    PubMed     Text format    


    February 2015
  58. CARRERA C
    High-risk melanoma patients: can unnecessary naevi biopsies be avoided?
    Br J Dermatol. 2015;172:313-5.
    PubMed     Text format    


    January 2015
  59. LONGO C, Moscarella E, Argenziano G, Lallas A, et al
    Reflectance confocal microscopy in the diagnosis of solitary pink skin tumors: Review of Diagnostic Clues.
    Br J Dermatol. 2015 Jan 30. doi: 10.1111/bjd.13689.
    PubMed     Text format     Abstract available


  60. KASSIANOS AP, Emery JD, Murchie P, Walter FM, et al
    Smartphone applications for melanoma detection by community, patient and generalist clinician users: a review.
    Br J Dermatol. 2015 Jan 20. doi: 10.1111/bjd.13665.
    PubMed     Text format     Abstract available


  61. JEUDY G, Dalac-Rat S, Bonniaud B, Hervieu A, et al
    Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Br J Dermatol. 2015;172:1454-5.
    PubMed     Text format    


  62. RICHTIG E, Arzberger E, Hofmann-Wellenhof R, Fink-Puches R, et al
    Assessment of changes in lentigo maligna during radiotherapy by in-vivo reflectance confocal microscopy: a pilot study.
    Br J Dermatol. 2015;172:81-7.
    PubMed     Text format     Abstract available


    December 2014
  63. LIVINGSTONE E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, et al
    Actual practice of melanoma follow-up and treatment in Germany: Results of a prospective, longitudinal cohort study.
    Br J Dermatol. 2014 Dec 15. doi: 10.1111/bjd.13612.
    PubMed     Text format     Abstract available


  64. MORTON RL
    Essential inputs for studies of cost-effectiveness analysis in melanoma.
    Br J Dermatol. 2014;171:1294-5.
    PubMed     Text format    


  65. NALDI L
    Melanoma excision: how deep must we go?
    Br J Dermatol. 2014;171:1291-2.
    PubMed     Text format    


  66. BERMUDEZ Y
    Ultraviolet involvement in melanocyte transformation to melanoma.
    Br J Dermatol. 2014;171:1289.
    PubMed     Text format    


    November 2014
  67. GONZALEZ-ALVAREZ T, Carrera C, Bennassar A, Vilalta A, et al
    Dermoscopy structures predictors of sentinel lymph node positivity in cutaneous melanoma.
    Br J Dermatol. 2014 Nov 21. doi: 10.1111/bjd.13552.
    PubMed     Text format     Abstract available


  68. HUNGER RE, Seyed Jafari SM, Angermeier S, Shafighi M, et al
    Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome.
    Br J Dermatol. 2014 Nov 13. doi: 10.1111/bjd.13478.
    PubMed     Text format     Abstract available


  69. LONGO C, Piana S, Marghoob A, Cavicchini S, et al
    Morphologic features of nevoid melanoma Results of a Multicenter Study of the International Dermoscopy Society.
    Br J Dermatol. 2014 Nov 12. doi: 10.1111/bjd.13524.
    PubMed     Text format     Abstract available


  70. GARCIA-CASADO Z, Traves V, Banuls J, Niveiro M, et al
    BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    Br J Dermatol. 2014 Nov 10. doi: 10.1111/bjd.13521.
    PubMed     Text format     Abstract available


  71. KITTLER H
    B-RAF, naevi and melanoma: a complex relationship.
    Br J Dermatol. 2014;171:931-932.
    PubMed     Text format    


    October 2014
  72. JIANG AJ, Rambhatla PV, Eide MJ
    A Systematic Review of Socioeconomic and Lifestyle Factors and Melanoma.
    Br J Dermatol. 2014 Oct 30. doi: 10.1111/bjd.13500.
    PubMed     Text format     Abstract available


  73. DABOUZ F, Barbe C, Lesage C, Le Clainche A, et al
    Clinical and histological features of head and neck melanoma: a population-based study in France.
    Br J Dermatol. 2014 Oct 21. doi: 10.1111/bjd.13489.
    PubMed     Text format     Abstract available


  74. MENIS D, Maronas-Jimenez L, Rodriguez-Peralto J, Martin-Llamas R, et al
    Two Spanish cases of Atypical Melanosis of the Foot, an early stage of Acral Lentiginous Melanoma in situ.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13485.
    PubMed     Text format     Abstract available


  75. PONTI G, Manfredini M, Tomasi A, Pellacani G, et al
    Distinctive clinical and dermoscopic features of BRAFp.V600K mutated melanomas.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13484.
    PubMed     Text format     Abstract available


  76. LYTH J, Eriksson H, Hansson J, Ingvar C, et al
    Trends in cutaneous malignant melanoma in Sweden 1997-2011: Thinner tumours and improved survival among men.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13483.
    PubMed     Text format     Abstract available


  77. EVANS CL
    Peering under the skin: measuring melanoma depth with ultrasound and optical coherence tomography.
    Br J Dermatol. 2014;171:690-1.
    PubMed     Text format    


    September 2014
  78. WATTS CG, Dieng M, Morton RL, Mann GJ, et al
    Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review.
    Br J Dermatol. 2014 Sep 10. doi: 10.1111/bjd.13403.
    PubMed     Text format     Abstract available


    August 2014
  79. STANGANELLI I, Longo C, Mazzoni L, Magi S, et al
    Integration of reflectance confocal microscopy in sequential dermoscopy follow-up improves melanoma detection accuracy.
    Br J Dermatol. 2014 Aug 25. doi: 10.1111/bjd.13373.
    PubMed     Text format     Abstract available


  80. MOSCARELLA E, Al Jalbout S, Piana S, Argenziano G, et al
    The stars within the melanocytic garden: Unusual variants of Spitz nevi.
    Br J Dermatol. 2014 Aug 13. doi: 10.1111/bjd.13347.
    PubMed     Text format     Abstract available


  81. LAWRENCE CM, Rahim R, Charlton F, Husain A, et al
    Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results.
    Br J Dermatol. 2014;171:298-303.
    PubMed     Text format     Abstract available


    July 2014
  82. BERETTI F, Manni P, Longo C, Argenziano G, et al
    CD271 is expressed in melanoma with more aggressive behavior with correlation of characteristic morphology in in vivo reflectance confocal microscopy.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13301.
    PubMed     Text format     Abstract available


  83. BRUGIERE C, Stefan A, Morice C, Cornet E, et al
    Vemurafenib skin phototoxicity is indirectly linked to UVA-MED decrease.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13300.
    PubMed     Text format     Abstract available


  84. TROMME I, Devleesschauwer B, Beutels P, Richez P, et al
    Health related quality of life in melanoma patients expressed as utilities and disability weights.
    Br J Dermatol. 2014 Jul 12. doi: 10.1111/bjd.13262.
    PubMed     Text format     Abstract available


  85. ANFORTH R, Carlos G, Clements A, Kefford R, et al
    Cutaneous Adverse Events in Patients Treated with BRAF Inhibitor Based Therapies for Metastatic Melanoma for Longer than 52 Weeks.
    Br J Dermatol. 2014 Jul 9. doi: 10.1111/bjd.13200.
    PubMed     Text format     Abstract available


    June 2014
  86. SELLA T, Goren I, Shalev V, Shapira H, et al
    Incidence Trends of Keratinocytic Skin Cancers and Melanoma in Israel 2006-2011.
    Br J Dermatol. 2014 Jun 28. doi: 10.1111/bjd.13213.
    PubMed     Text format     Abstract available


  87. GAMBICHLER T, Kempka J, Kampilafkos P, Bechara FG, et al
    Clinicopathological characteristics of 270 lentigo maligna and lentigo maligna melanoma patients: data of a German Skin Cancer Center.
    Br J Dermatol. 2014 Jun 24. doi: 10.1111/bjd.13204.
    PubMed     Text format     Abstract available


  88. DE TROYA-MARTIN M, Rivas-Ruiz F, Blazquez-Sanchez N, Fernandez-Canedo I, et al
    Spanish version of the "skin cancer index". A questionnaire for measuring quality of life in patients with cervicofacial non-melanoma skin cancer.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13173.
    PubMed     Text format     Abstract available


  89. ERIKSSON H, Frohm-Nilsson M, Jaras J, Kanter-Lewensohn L, et al
    Prognostic factors in localized invasive primary cutaneous malignant melanoma -results of a large population-based study.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13171.
    PubMed     Text format     Abstract available


    May 2014
  90. PELLACANI G, Pepe P, Casari A, Longo C, et al
    Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study.
    Br J Dermatol. 2014 May 29. doi: 10.1111/bjd.13148.
    PubMed     Text format     Abstract available


  91. MEYER N, Lauwers-Cances V, Lourari S, Laurent J, et al
    High frequency ultrasonography but not 930nm-optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study.
    Br J Dermatol. 2014 May 23. doi: 10.1111/bjd.13129.
    PubMed     Text format     Abstract available


  92. MALVEHY J, Hauschild A, Curiel-Lewandrowski C, Mohr P, et al
    Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multi-centre, prospective and blinded clinical trial on efficacy and safety.
    Br J Dermatol. 2014 May 19. doi: 10.1111/bjd.13121.
    PubMed     Text format     Abstract available


  93. CHEVOLET I, Speeckaert R, Haspeslagh M, Neyns B, et al
    Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
    Br J Dermatol. 2014 May 10. doi: 10.1111/bjd.13100.
    PubMed     Text format     Abstract available


    April 2014
  94. POZZOBON FC, Puig-Butille JA, Gonzalez-Alvarez T, Carrera C, et al
    Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13069.
    PubMed     Text format     Abstract available


  95. TALAGANIS JA, Biello K, Plaka M, Polydorou D, et al
    Demographic, behavioural and physician-related determinants of early melanoma detection in a low incidence population.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13068.
    PubMed     Text format     Abstract available


  96. CHEVALIER V, Barbe C, Le Clainche A, Arnoult G, et al
    Comparison of Anatomic Locations of Cutaneous Melanoma in Men and Women: A Population-Based Study in France.
    Br J Dermatol. 2014 Apr 11. doi: 10.1111/bjd.13052.
    PubMed     Text format     Abstract available


  97. KOSE K, Cordova M, Duffy M, Flores ES, et al
    Video-Mosaicing of Reflectance Confocal Images For Examination of Extended Areas of Skin In Vivo.
    Br J Dermatol. 2014 Apr 10. doi: 10.1111/bjd.13050.
    PubMed     Text format     Abstract available


  98. HOLLESTEIN LM, Nijsten T
    The association between beta-blockers and melanoma survival: evidence of absence or absence of evidence?
    Br J Dermatol. 2014;170:764-5.
    PubMed     Text format    


    March 2014
  99. ROTA M, Negri E, Pelucchi C, La Vecchia C, et al
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis: reply from authors.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12996.
    PubMed     Text format     Abstract available


  100. SUN V, Zhou WB, Majid S, Kashani-Sabet M, et al
    MicroRNA-mediated regulation of melanoma.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12989.
    PubMed     Text format     Abstract available


  101. PASTUSHENKO I, Vermeulen PB, Van den Eynden GG, Rutten A, et al
    Mechanisms of tumour vascularisation in cutaneous malignant melanoma: clinical implications.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12973.
    PubMed     Text format     Abstract available


  102. CHEN GC, Zhang Y
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12971.
    PubMed     Text format     Abstract available


  103. PICARD M, Pham Dang N, D'Incan M, Mansard S, et al
    Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
    Br J Dermatol. 2014 Mar 6. doi: 10.1111/bjd.12939.
    PubMed     Text format     Abstract available


  104. DE WAAL AC, van Harten-Gerritsen AS, Aben KK, Kiemeney LA, et al
    Impact of mitotic activity on the pathological sub-staging of pT1 cutaneous melanoma.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12898.
    PubMed     Text format     Abstract available


  105. MCCOURT C, Coleman HG, Murray LJ, Cantwell MM, et al
    Beta-blocker usage after malignant melanoma diagnosis and survival: A population-based nested case-control study.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12894.
    PubMed     Text format     Abstract available


  106. FORSEA AM, Del Marmol V, Stratigos A, Geller AC, et al
    Melanoma Prognosis in Europe: Far from Equal.
    Br J Dermatol. 2014 Mar 3. doi: 10.1111/bjd.12923.
    PubMed     Text format     Abstract available


    February 2014
  107. ROTA M, Pasquali E, Bellocco R, Bagnardi V, et al
    Alcohol drinking and cutaneous melanoma risk - A systematic review and dose-risk meta-analysis.
    Br J Dermatol. 2014 Feb 3. doi: 10.1111/bjd.12856.
    PubMed     Text format     Abstract available


  108. SACHSE MM, Wagner G
    Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
    Br J Dermatol. 2014;170:475-7.
    PubMed     Text format    


    January 2014
  109. ECHEVERRIA B, Bulliard JL, Guillen C, Nagore E, et al
    Indicators for the total number of melanocytic naevi: an adjunct for screening campaigns. Observational study on 292 patients.
    Br J Dermatol. 2014;170:144-9.
    PubMed     Text format     Abstract available


  110. RIVERS JK
    Skin cancer: more than skin deep?
    Br J Dermatol. 2014;170:8.
    PubMed     Text format    


  111. FOGARTY GB, Hong A, Scolyer RA, Lin E, et al
    Radiotherapy for lentigo maligna: a literature review and recommendations for treatment.
    Br J Dermatol. 2014;170:52-8.
    PubMed     Text format     Abstract available


    August 2013
  112. DIFFEY B
    Sunbeds and young people: an easy target for legislation?
    Br J Dermatol. 2013;169:236-7.
    PubMed     Text format    


    July 2013
  113. ANFORTH R , Blumetti TC, Clements A, Kefford R, et al
    Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors.
    Br J Dermatol. 2013 Jul 20. doi: 10.1111/bjd.12519.
    PubMed     Text format     Abstract available


    June 2013
  114. BLACK N
    Patient-reported outcome measures in skin cancer.
    Br J Dermatol. 2013;168:1151.
    PubMed     Text format    


  115. DE VRIES K, Rellum R, Habets JM, Prens EP, et al
    A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod.
    Br J Dermatol. 2013;168:1362-4.
    PubMed     Text format    


    March 2013
  116. GIBBONS E , Casanas I Comabella C, Fitzpatrick R
    A structured review of patient-reported outcome measures for patients with skin cancer, 2013.
    Br J Dermatol. 2013 Mar 14. doi: 10.1111/bjd.12310.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.

Design: